Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients
Status
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to better understand a new type of radiology test called positron emission tomography (PET) with carbon 11 methionine to determine which patients have a beneficial effect from anti-cancer therapy with the drug docetaxel.
Full description
In the week before the patients first dose of chemotherapy they will receive a C11 methionine PET scan which takes about 90 minutes. C11 methionine is a radioactively labeled amino acid that is given to the patient intravenously.
Eighteen to twenty days after the patients first dose of docetaxel chemotherapy, they will have another C11 methionine PET scan which is identical to the first scan.
At the end of three cycles of docetaxel chemotherapy (about 2 and 1/2 months on study) another C11 methionine PET scan will be done.
The PET scans will show how well the tumor is taking up methionine.
Sex
Ages
Volunteers
Inclusion criteria
- Metastatic hormone-refractory prostate cancer patients who are planned to begin every 3-week docetaxel chemotherapy
- Progression after androgen deprivation therapy
- Serum testosterone < 50ng/ml
- 18 years of age or older
Exclusion criteria
- Prior taxane therapy
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal